Market Exclusive

Analyst Activity – Laidlaw Reiterates Hold on Intercept Pharmaceuticals (NASDAQ:ICPT)

Analyst Ratings For Intercept Pharmaceuticals (NASDAQ:ICPT)

Today, Laidlaw reiterated its Hold rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of $119.00.

There are 2 sell ratings, 4 hold ratings, 10 buy ratings on the stock.

The current consensus rating on Intercept Pharmaceuticals (NASDAQ:ICPT) is Buy (Score: 2.50) with a consensus target price of $203.79 per share, a potential 83.99% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Intercept Pharmaceuticals (NASDAQ:ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) has insider ownership of 4.50% and institutional ownership of 84.27%.

Recent Trading Activity for Intercept Pharmaceuticals (NASDAQ:ICPT)
Shares of Intercept Pharmaceuticals closed the previous trading session at 110.76 down -6.37 -5.44% with 1,763,421 shares trading hands.

Exit mobile version